TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10332946
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of naps and modafinil
Study: 1712266
Drug: Cilazapril and
Normalized name: cilazapril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril and Propranolol combination
Study: 27579803
Drug: MTPT and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTPT and medicine ball exercises
Study: 25799801
Drug: Fentanyl 20
Normalized name: fentaNYL 200 mcg buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 20 microgram (0.4 ml) added to 0.5% bupivacaine heavy 2 ml (Group B)
Study: 25799801
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine heavy 2.4 ml (Group A)
Study: 17200838
Drug: MK-0524 25
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0524 25 mg
Study: 17200838
Drug: MK-0524 100
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0524 100 mg
Study: 12365909
Drug: Verteporfin therapy
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Verteporfin therapy (original assignment)
Study: 16495883
Drug: Biological supplement
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological supplement (FloRelax®, Sanofi Winthrop) for 6 weeks
Study: 8087928
Drug: Chelation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chelation therapy (EDTA)
Study: 2571759
Drug: Pyrimethamine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrimethamine (25 mg weekly for suppressive prophylaxis)
Study: 2571759
Drug: Pyrimethamine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrimethamine (25 mg weekly after chloroquine 25 mg/kg)
Study: 2571759
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no prophylaxis after chloroquine 25 mg/kg)
Study: 16223747
Drug: hGH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: hGH treatment (4 IU/m2/day for two years)
Study: 11054340
Drug: Topical dexamethasone
Normalized name: dexamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dexamethasone (0.1%) administered four times daily
Study: 11054340
Drug: Topical dexamethasone
Normalized name: dexamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dexamethasone (0.1%) administered twice daily
Study: 23808594
Drug: Nimodipine AP
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nimodipine AP (Tropocer®) 90 mg once daily
Study: 23808594
Drug: Nimodipine (Nimotop®)
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nimodipine (Nimotop®) 30 mg three times daily
Study: 18272244
Drug: Androgenic anabolic
Normalized name: ANDROGENS/ANABOLICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgenic anabolic steroids
Study: 18272244
Drug: Drug-free bodybuilders
Normalized name: HERBAL BODYBUILDING CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-free bodybuilders
Study: 28483498
Drug: 100% RDA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% RDA (0.8g·kg‐1·d‐1) plus placebo injections
Study: 28483498
Drug: 100% RDA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% RDA (0.8g·kg‐1·d‐1) plus 100mg testosterone enanthate injections
Study: 28483498
Drug: 163% RDA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 163% RDA (1.3g·kg‐1·d‐1) plus placebo injections
Study: 28483498
Drug: 163% RDA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 163% RDA (1.3g·kg‐1·d‐1) plus testosterone injections
Study: 23904400
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus leuprolide acetate
Study: 21707189
Drug: Prize contingency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prize contingency management (CM) treatment
Study: 2568639
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg zuclopenthixol daily
Study: 2568639
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg haloperidol in the morning and 5 mg levomepromazine in the evening
Study: 893737
Drug: Intravenous hydralazine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydralazine, 0.15 mg/kg
Study: 893737
Drug: Intravenous propranolol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propranolol, 0.1 mg/kg
Study: 893737
Drug: Intravenous hydralazine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydralazine, 0.15 mg/kg after phentolamine infusion (0.01 or 0.02 mg/kg per minute)
Study: 893737
Drug: Intravenous hydralazine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydralazine, 0.30 mg/kg
Study: 893737
Drug: Intravenous hydralazine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydralazine, 0.60 mg/kg
Study: 17729060
Drug: Salmeterol (a
Normalized name: salmeterol (as xinafoate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (a long-acting β2-agonist) in combination with fluticasone propionate (an inhaled corticosteroid)
Study: 17729060
Drug: Tiotropium bromide
Normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiotropium bromide (an anticholinergic bronchodilator)
Study: 11818765
Drug: loratadine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: loratadine (20 mg)
Study: 11818765
Drug: ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine (300 mg)
Study: 8678246
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate (40 mg.kg‐1)
Study: 25775661
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of trichloroacetic acid (TCA) 50% solution once weekly
Study: 22177370
Drug: Murraya koenigii
Normalized name: MURRAYA KOENIGII WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Murraya koenigii and Tribulus terrestris-based oral formulation (2 capsules BID for 12 weeks)
Study: 22177370
Drug: Tamsulosin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (400 μg once daily for 12 weeks)
Study: 10886048
Drug: Sucralfate 1
Normalized name: sucralfate 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate 1 g t.d.s., amoxycillin 500 mg t.d.s., and clarithromycin 400 mg b.d. (SAC regimen)
Study: 10886048
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg o.m. with the same antimicrobial medications (LAC regimen)
Study: 2871860
Drug: Two drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two drug regimen: vincristine 2 mg m‐2 (maximum 2mg) followed by methotrexate 200 mgm‐2, given every three weeks for 54 weeks.
Study: 2871860
Drug: Three drug
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three drug regimen: vincristine-methotrexate treatment alternating every three weeks with doxorubicin 60 mg m‐2 for 54 weeks.
Study: 31258136
Drug: 10-day bismuth-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day bismuth-containing quadruple therapy (BQT)
Study: 25074637
Drug: Dihydrexidine (DAR-0100A)
Normalized name: Magnesium dihydroxide
DrugBank: Dihydrexidine (DB12890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydrexidine (DAR-0100A) 15 mg/150 ml of normal saline administered intravenously over 30 min
Study: 19949360
Drug: Pentavalent human-bovine
Normalized name: human-bovine reassortant rotavirus strain G1 vaccine / human-bovine reassortant rotavirus strain G2 vaccine / human-bovine reassortant rotavirus strain G3 vaccine / human-bovine reassortant rotavirus strain G4 vaccine / human-bovine reassortant rotavirus strain P1A[8] vaccine Oral Suspension [RotaTeq]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentavalent human-bovine reassortant rotavirus vaccine
Study: 16391891
Drug: Pamidronate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (1 mg/kg)
Study: 16391891
Drug: Synthetic human
Normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synthetic human calcitonin (1.5 mg)
Study: 15220685
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg once daily, amoxicillin 1 g, clarithromycin 500 mg (EAC1 group, n = 52)
Study: 15220685
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg (OAC group, n = 52)
Study: 15220685
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg (EAC2 group, n = 52)
Study: 8384011
Drug: Meglumine antimonate
Normalized name: meglumine antimonate
DrugBank: Meglumine antimoniate (DB13732)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meglumine antimonate (10 mg of antimony/kg intramuscularly, twice a day for 20 days)
Study: 8384011
Drug: Pentamidine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentamidine (2 mg/kg every other day intramuscularly, for a total of seven injections)
Study: 8384011
Drug: Pentamidine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentamidine (2 mg/kg every other day for a total of only four injections)
Study: 8384011
Drug: Itraconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (200 mg orally, twice a day for 28 days)
Study: 29505880
Drug: Amoxicillin for
Normalized name: Amoxicillin for Oral Suspension
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin for 14 days
Study: 29505880
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (PCV, amoxicillin, doxycycline)
Study: 24530993
Drug: Hexyl 5‐aminolevulinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexyl 5‐aminolevulinate hydrochloride (HAL) at a dose of 6.25mg/ml
Study: 24530993
Drug: Hexyl 5‐aminolevulinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexyl 5‐aminolevulinate hydrochloride (HAL) at a dose of 50mg/ml
Study: 22932169
Drug: BUD/FORM (160/4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUD/FORM (160/4.5 µg/inhalation) + as-needed BUD/FORM (640/18 µg/d)
Study: 22932169
Drug: SALM/FP (100/1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: SALM/FP (100/1000 µg/d) + as-needed terbutaline (0.4 mg/inhalation)
Study: 12025234
Drug: Inhibitors of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibitors of receptor tyrosine kinases (RTK) and Ras
Study: 12025234
Drug: Natural and
Normalized name: Natural and artifical flavoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural and synthetic compounds, monoclonal antibodies, and antisense oligonucleotides as inhibitors of signal transduction
Study: 11773987
Drug: verapamil SR/trandolapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil SR/trandolapril 180/2 mg (VT)
Study: 11773987
Drug: enalapril/hydroclorothiazide 20/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril/hydroclorothiazide 20/12.5 mg (EH)
Study: 9022869
Drug: Knowledge-and-skills-building workshop
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge-and-skills-building workshop for chemical dependency staff on treatment of nicotine dependence
Study: 3782428
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC; 150 mg) for 5 days
Study: 27277213
Drug: ART with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART with TB treatment
Study: 27277213
Drug: TB treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TB treatment only
Study: 18711188
Drug: PF-3512676 (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-3512676 (0.2 mg/kg subcutaneously on days 8 and 15 of each 3-week cycle)
Study: 12558709
Drug: Topical collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical collagen daily
Study: 12558709
Drug: Topical hydrocolloid
Normalized name: psyllium hydrocolloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical hydrocolloid twice weekly
Study: 9869576
Drug: Double combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double combination of zidovudine (ZDV) plus didanosine (ddI)
Study: 9869576
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination of nevirapine (NVP) plus ZDV plus ddI
Study: 9869576
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination of NVP plus ZDV plus ddI
Study: 1669595
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg loratadine once daily
Study: 26375541
Drug: Fentanyl ITS
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl ITS (40 mcg/activation)
Study: 26375541
Drug: IV PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV PCA morphine (1 mg/dose)
Study: 15177522
Drug: Pravastatin 10
Normalized name: pravastatin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 10 mg/d for 6 months
Study: 15177522
Drug: Probucol 500
Normalized name: probucol 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol 500 mg/d for 6 months
Study: 11589258
Drug: Tramadol/APAP (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol/APAP (37.5 mg/325 mg)
Study: 11589258
Drug: Codeine/APAP (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine/APAP (30 mg/300 mg)
Study: 11477815
Drug: Xianzhen Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xianzhen Tablet (XZT) treated group, 30 patients, 8 weeks treatment
Study: 8608658
Drug: Concurrent ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent ACE inhibitor
Study: 2756523
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of propafenone on days 1 and 4, 1200 mg/day on days 2 and 3
Study: 2756523
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of propafenone on days 1 and 4, 1200 mg/day on days 2 and 3
Study: 25979190
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) applied during the bone consolidation period following mandibular distraction osteogenesis.
Study: 18272020
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg morphine sulphate (p.o.)
Study: 15055563
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide aqueous nasal spray (TAA AQ), 220 microg everyday for 21 days
Study: 15055563
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray (FP AQ), 200 microg everyday for 21 days
Study: 9460590
Drug: Atenolol therapy
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol therapy for 6 months
Study: 3456621
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg PGE2/day/patient (5 mg every 4 hours, 4 times a day)
Study: 3456621
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg lactose/day/patient (placebo)
Study: 23442835
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg, Esomeprazole 40 mg
Study: 23442835
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg, Lansoprazole 30 mg
Study: 19881393
Drug: Azithromycin 30
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 30 mg/kg
Study: 19881393
Drug: Azithromycin 20
Normalized name: azithromycin 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 20 mg/kg
Study: 19881393
Drug: Erythromycin 50
Normalized name: erythromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 50 mg/kg for 5 days
Study: 18948636
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) 1.8 g daily for 3 months
Study: 17304477
Drug: Teletherapy combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teletherapy combined with radioisotope therapy
Study: 17304477
Drug: Radioisotope therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioisotope therapy
Study: 17304477
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (radiotherapy and radioisotopes)
Study: 11908358
Drug: Colgate Winterfresh
Normalized name: Colgate
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colgate Winterfresh Gel (0.243% sodium fluoride)
Study: 8731383
Drug: Insulin-like growth
Normalized name: Insulin-like growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-like growth factor I (100 micrograms/kg)
Study: 3862020
Drug: Nonsteroidal anti‐inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti‐inflammatory agents
Study: 3862020
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of corticosteroids and nonsteroidal anti‐inflammatory agents
Study: 23508601
Drug: Intervention (point-of-care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention (point-of-care education, coaching, medication intensification)
Study: 16736000
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplementation (1.2 mg day(‐1) for 12 weeks)
Study: 8273956
Drug: NMB-assisted oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: NMB-assisted oral intubation (succinylcholine 1.5 mg/kg IV)
Study: 8273956
Drug: NMB-assisted oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: NMB-assisted oral intubation
Study: 30843497
Drug: Ma‐al‐Shaeer (MS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ma‐al‐Shaeer (MS) 15 g of dried MS powder twice daily for 14 days
Study: 30843497
Drug: Fexofenadine (FX)
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine (FX) 60 mg twice daily for 14 days
Study: 25495272
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (5-day dual therapy with pantoprazole plus amoxicillin, followed by 5-day triple therapy with pantoprazole plus clarithromycin and metronidazole)
Study: 25495272
Drug: Reverse sequential
Normalized name: OraVerse
DrugBank: Phentolamine (DB00692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reverse sequential therapy (5-day triple therapy with pantoprazole plus clarithromycin and metronidazole, followed by 5-day dual therapy with pantoprazole plus amoxicillin)
Study: 25495272
Drug: Reverse sequential
Normalized name: OraVerse
DrugBank: Phentolamine (DB00692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reverse sequential therapy
Study: 17034446
Drug: Reimbursement for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reimbursement for smoking cessation treatment (SCT) for 6 months
Study: 15321933
Drug: Remifentanil target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil target concentration of 5 ng ml(‐1)
Study: 15321933
Drug: Remifentanil target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil target concentration of 10 ng ml(‐1)
Study: 15321933
Drug: Remifentanil target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil target concentration of 15 ng ml(‐1)
Study: 3109574
Drug: Subcutaneous calcium
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous calcium heparin
Study: 19968833
Drug: Bromocriptine 2.5
Normalized name: bromocriptine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine 2.5 mg/day
Study: 2444307
Drug: Bromocriptine 5
Normalized name: bromocriptine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine 5 mg/day
Study: 19968833
Drug: Bromocriptine 10
Normalized name: bromocriptine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine 10 mg/day
Study: 19968833
Drug: Bromocriptine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (all doses)
Study: 18441691
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment adherence
Study: 18441691
Drug: Reasons for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reasons for missed drug intake
Study: 18441691
Drug: Barriers to
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barriers to regular drug intake
Study: 9546995
Drug: Device therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Device therapy in a blinded manner
Study: 8391856
Drug: N-9 twice
Normalized name: (+/-)-N-methylephedrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-9 twice a day
Study: 24080019
Drug: Drug naive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug naive controls
Study: 15339055
Drug: Carboplatin/gemcitabine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin/gemcitabine combination
Study: 15339055
Drug: Carboplatin/gemcitabine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin/gemcitabine combination (3-week schedule)
Study: 8432481
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose cyclosporin (4.1 mg/kg/day)
Study: 2835836
Drug: Topical antibiotic
Normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical antibiotic preparation (neomycin, bacitracin, and polymyxin B)
Study: 24201233
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) up to 2 g/d
Study: 19370425
Drug: Proton-beam therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton-beam therapy (PBT)
Study: 19370425
Drug: 3D conformal
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3D conformal X-ray therapy (3D-CRT)